[{"orgOrder":0,"company":"GelMEDIX","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Hyaluronic Acid","moa":"","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"GelMEDIX","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Hydrogel Implant","sponsorNew":"GelMEDIX \/ HTL","highestDevelopmentStatusID":"1","companyTruncated":"GelMEDIX \/ HTL"}]

Find Clinical Drug Pipeline Developments & Deals by GelMEDIX

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Duphat
Not Confirmed
Duphat
Not Confirmed

Details : This investment supports development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therapies. HTL will produce methacrylate hyaluronic acid, a key component for specific parameters across the G...

Brand Name : Undisclosed

Molecule Type : Undisclosed

Upfront Cash : Undisclosed

March 10, 2022

Lead Product(s) : Regenerative Medicine,Hyaluronic Acid

Therapeutic Area : Ophthalmology

Highest Development Status : Undisclosed

Sponsor : HTL Biotechnology

Deal Size : Undisclosed

Deal Type : Financing

blank